

Pathophysiological mechanisms of hypertensive left ventricular hypertrophy: optimising regression

Submission date 12/09/2003	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 12/09/2003	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 24/09/2012	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof SG Ball

Contact details
Yorkshire Heart Centre
G Floor
Jubilee Wing
Leeds General Infirmary
Leeds
United Kingdom
LS1 3EX
+44 0113 243 2799x22185
s.g.ball@leeds.ac.uk

Additional identifiers

Protocol serial number
N0436117967

Study information

Scientific Title

Study objectives

We aim to investigate the mechanisms responsible for the development of hypertensive left ventricular hypertrophy (LVH), and determine the optimal treatment strategy. We aim to investigate the mechanisms responsible for the development of hypertensive left ventricular hypertrophy (LVH), and determine the optimal treatment strategy. LVH is thought to be related to activation of the renin-angiotensin system and the sympathetic nervous system, in addition to the effect of the high blood pressure. We will accurately determine baseline LV mass using cardiac MRI as well as measuring the degree of humoral and neural activation. Patients will be randomised to different combinations of standard blood pressure treatments for 4 months and then reassessed. We hope to determine whether controlling blood pressure by specifically targeting the neurohumoral activation is more effective in regressing LVH than simple blood pressure control alone. It is hoped that this study will yield useful information regarding the best treatment for hypertensive LVH.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Cardiovascular: Hypertensive left ventricular hypertrophy (LVH)

Interventions

Laboratory study; Randomised controlled trial, Random allocation to different combinations of standard blood pressure treatments.

Random allocation to:

- A. Treatment one
- B. Treatment two
- C. Treatment three
- D. Treatment four

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Magnetic resonance imaging (MRI) measurement of left ventricular mass regression.

Key secondary outcome(s)

Not provided at time of registration

Completion date

30/11/2009

Eligibility

Key inclusion criteria

All recruited patients will have hypertension and left ventricular hypertrophy.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/08/2002

Date of final enrolment

30/11/2009

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Yorkshire Heart Centre

Leeds

United Kingdom

LS1 3EX

Sponsor information

Organisation

Department of Health (UK)

Funder(s)

Funder type

Government

Funder Name

Leeds Teaching Hospitals NHS Trust (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2012		Yes	No